Immunotherapy dostarlimab gains FDA approval for treatment of recurrent and advanced endometrial cancer
Full article:

The FDA has given accelerated approval for the immunotherapy agent dostarlimab (Jemperli) to treat recurrent and advanced endometrial cancer that has a biomarker called mismatch repair deficiency (dMMR). This adds a new treatment option for people with recurrent or advanced endometrial cancer. (posted 5/18/21)

Este artículo está disponible en español.

Questions To Ask Your Health Care Provider

Open Clinical Trials

The following studies are enrolling people with advanced endometrial cancer.  

A number of other clinical trials for patients with endometrial cancer can be found here.


FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.